XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1Close
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended 6 Months Ended
Jun. 29, 2024
Jul. 01, 2023
Jun. 29, 2024
Jul. 01, 2023
Revenues        
Total revenues $ 10,541 $ 10,687 $ 20,886 $ 21,397 Close
Costs and operating expenses:        
Selling, general and administrative expenses 2,111 2,145 4,293 4,264
Research and development expenses 339 345 670 691
Restructuring and other costs 77 183 106 295
Total costs and operating expenses 8,722 9,109 17,404 18,256 Close
Operating income 1,820 1,578 3,483 3,141 Close
Interest income 295 178 574 324 Close
Interest expense (354) (326) (717) (626) Close
Other income/(expense) 5 0 14 (46) CloseClose
Total Other Income Expenses -54.0 -148.0 -129.0 -348.0 0.0 Close
Income before income taxes 1,765 1,430 3,354 2,793 CloseClose
Provision for income taxes (128) (52) (408) (98) Close
Equity in earnings/(losses) of unconsolidated entities (84) (16) (61) (41) Close
Net income 1,553 1,362 2,885 2,654 Close
Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest 6 1 9 4
Net income attributable to Thermo Fisher Scientific Inc. $ 1,548 $ 1,361 $ 2,875 $ 2,650
Earnings per share attributable to Thermo Fisher Scientific Inc.        
Basic (in dollars per share) $ 4.05 $ 3.53 $ 7.53 $ 6.86
Diluted (in dollars per share) $ 4.04 $ 3.51 $ 7.50 $ 6.83
Weighted average shares        
Basic (in shares) 382 386 382 386
Diluted (in shares) 383 388 383 388
Product revenues        
Revenues        
Total revenues $ 6,163 $ 6,271 $ 12,118 $ 12,675
Costs and operating expenses:        
Cost of revenues 3,080 3,278 6,019 6,615
Service revenues        
Revenues        
Total revenues 4,378 4,416 8,768 8,722
Costs and operating expenses:        
Cost of revenues $ 3,114 $ 3,158 $ 6,315 $ 6,391